GX-188E, GX-I7

BIOLOGICAL2 trials

Sponsors

Seoul St. Mary's Hospital, Yonsei University

Conditions

Cervical Intraepithelial Neoplasia 3Head and Neck Squamous Cell Carcinoma

Phase 2

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Active, not recruitingNCT05286060

Yonsei UniversityHead and Neck Squamous Cell Carcinoma

Start: 2022-03-01End: 2026-12-01Target: 56Updated: 2026-02-09

Unknown Phase

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Seoul St. Mary's HospitalCervical Intraepithelial Neoplasia 3

Start: 2017-05-30End: 2018-10-31Target: 50Updated: 2017-07-02

Related Papers

Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.

Journal of Clinical Oncology2023-06-013 citations